Skip to main content
Top
Published in: Advances in Therapy 1/2024

Open Access 22-11-2023 | Urticaria | Commentary

A Patient Charter for Chronic Urticaria

Authors: Marcus Maurer, Mónica Albuquerque, Jean-Nicolas Boursiquot, Elaine Dery, Ana Giménez-Arnau, Kiran Godse, Guillermo Guitiérrez, Amin Kanani, Gina Lacuesta, Jessica McCarthy, Simon Nigen, Tonya Winders

Published in: Advances in Therapy | Issue 1/2024

Login to get access

Abstract

Chronic urticaria (CU) is the recurring development of wheals (aka “hives” or “welts”), angioedema, or both for more than 6 weeks. Wheals and angioedema occur with no definite triggers in chronic spontaneous urticaria, and in response to known and definite physical triggers in chronic inducible urticaria. Approximately 1.4% of individuals globally will have CU during their lifetime. The itching and physical discomfort associated with CU have a profound impact on daily activities, sexual function, work or school performance, and sleep, causing significant impairment in a patient’s physical and mental quality of life. CU also places a financial burden on patients and healthcare systems. Patients should feel empowered to self-advocate to receive the best care. The voice of the patient in navigating the journey of CU diagnosis and management may improve patient–provider communication, thereby improving diagnosis and outcomes. A collaboration of patients, providers, advocacy organizations, and pharmaceutical representatives have created a patient charter to define the realistic and achievable principles of care that patients with CU should expect to receive. Principle (1): I deserve an accurate and timely diagnosis of my CU; Principle (2): I deserve access to specialty care for my CU; Principle (3): I deserve access to innovative treatments that reduce the burden of CU on my daily life; Principle (4): I deserve to be free of unnecessary treatment-related side-effects during the management of my CU; and Principle (5): I expect a holistic treatment approach to address all the components of my life impacted by CU. The stated principles may serve as a guide for healthcare providers who care for patients with CU and translate into better patient–physician communication. In addition, we urge policymakers and authors of CU treatment guidelines to consider these principles in their decision-making to ensure the goals of the patient are achievable.
Literature
1.
go back to reference Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.PubMedCrossRef Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.PubMedCrossRef
2.
go back to reference Kolkhir P, Pogorelov D, Darlenski R, Caminati M, Tanno LK, Le Pham D, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11:14.PubMedPubMedCentralCrossRef Kolkhir P, Pogorelov D, Darlenski R, Caminati M, Tanno LK, Le Pham D, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11:14.PubMedPubMedCentralCrossRef
3.
go back to reference Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–7.PubMedCrossRef Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–7.PubMedCrossRef
4.
go back to reference Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.PubMedCrossRef Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.PubMedCrossRef
5.
go back to reference Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533.PubMedPubMedCentralCrossRef Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533.PubMedPubMedCentralCrossRef
6.
go back to reference Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.PubMedCrossRef Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.PubMedCrossRef
7.
go back to reference Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report. Allergy. 2011;66:317–30.PubMedCrossRef Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report. Allergy. 2011;66:317–30.PubMedCrossRef
8.
go back to reference Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J. 2021;14:100546.PubMedPubMedCentralCrossRef Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J. 2021;14:100546.PubMedPubMedCentralCrossRef
9.
go back to reference Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol. 2011;25:1194–9.PubMedCrossRef Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol. 2011;25:1194–9.PubMedCrossRef
10.
go back to reference Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–16.PubMedCrossRef Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–16.PubMedCrossRef
11.
go back to reference Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8:551–8.PubMedPubMedCentralCrossRef Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8:551–8.PubMedPubMedCentralCrossRef
12.
go back to reference Hoskin B, Ortiz B, Paknis B, Kavati A. Humanistic burden of refractory and nonrefractory chronic idiopathic urticaria: a real-world study in the United States. Clin Ther. 2019;41:205–20.PubMedCrossRef Hoskin B, Ortiz B, Paknis B, Kavati A. Humanistic burden of refractory and nonrefractory chronic idiopathic urticaria: a real-world study in the United States. Clin Ther. 2019;41:205–20.PubMedCrossRef
13.
go back to reference Huang Y, Xiao Y, Zhang X, Li J, Chen X, Shen M. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39.PubMedCrossRef Huang Y, Xiao Y, Zhang X, Li J, Chen X, Shen M. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39.PubMedCrossRef
14.
go back to reference Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99:1091–8.PubMed Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99:1091–8.PubMed
15.
16.
go back to reference Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, et al. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: a real-world study in the United States. Allergy Asthma Proc. 2018;39:201–11.PubMedCrossRef Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, et al. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: a real-world study in the United States. Allergy Asthma Proc. 2018;39:201–11.PubMedCrossRef
17.
go back to reference Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.PubMedPubMedCentralCrossRef Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.PubMedPubMedCentralCrossRef
18.
go back to reference Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45:101.PubMedPubMedCentralCrossRef Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45:101.PubMedPubMedCentralCrossRef
19.
go back to reference Chung WH, Chu CY, Huang YH, Wang WM, Yang CH, Tsai TF. Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria. J Formos Med Assoc. 2016;115:968–80.PubMedCrossRef Chung WH, Chu CY, Huang YH, Wang WM, Yang CH, Tsai TF. Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria. J Formos Med Assoc. 2016;115:968–80.PubMedCrossRef
20.
go back to reference Hacard F, Giraudeau B, d’Acremont G, Jegou MH, Jonville-Bera AP, Munck S, et al. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol. 2021;185:658–60.PubMedPubMedCentralCrossRef Hacard F, Giraudeau B, d’Acremont G, Jegou MH, Jonville-Bera AP, Munck S, et al. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol. 2021;185:658–60.PubMedPubMedCentralCrossRef
21.
go back to reference Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45:547–65.PubMedCrossRef Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45:547–65.PubMedCrossRef
22.
go back to reference Esteves Caldeira L, Paulino M, Coutinho C, Neto M, Pereira Barbosa M, Costa C. Clinical experience of a specialized urticaria outpatient clinic from a Portuguese UCARE. Eur Ann Allergy Clin Immunol. 2023;55:9–18.PubMedCrossRef Esteves Caldeira L, Paulino M, Coutinho C, Neto M, Pereira Barbosa M, Costa C. Clinical experience of a specialized urticaria outpatient clinic from a Portuguese UCARE. Eur Ann Allergy Clin Immunol. 2023;55:9–18.PubMedCrossRef
23.
go back to reference Maurer M, Weller K, Magerl M, Maurer RR, Vanegas E, Felix M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study. World Allergy Organ J. 2020;13: 100475.PubMedPubMedCentralCrossRef Maurer M, Weller K, Magerl M, Maurer RR, Vanegas E, Felix M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study. World Allergy Organ J. 2020;13: 100475.PubMedPubMedCentralCrossRef
25.
go back to reference Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2019;15:56.PubMedPubMedCentralCrossRef Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2019;15:56.PubMedPubMedCentralCrossRef
26.
go back to reference Zuberbier T, Pfrommer C, Specht K, Vieths S, Bastl-Borrmann R, Worm M, et al. Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. J Allergy Clin Immunol. 2002;109:343–8.PubMedCrossRef Zuberbier T, Pfrommer C, Specht K, Vieths S, Bastl-Borrmann R, Worm M, et al. Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. J Allergy Clin Immunol. 2002;109:343–8.PubMedCrossRef
27.
28.
go back to reference Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780–802.PubMedCrossRef Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780–802.PubMedCrossRef
29.
go back to reference Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, et al. Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis. J Allergy Clin Immunol Pract. 2020;8:2360-9.e1.PubMedCrossRef Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, et al. Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis. J Allergy Clin Immunol Pract. 2020;8:2360-9.e1.PubMedCrossRef
30.
go back to reference Oliver ET, Hogan MB. Eliminating low-value medical care in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2020;8:2370–1.PubMedCrossRef Oliver ET, Hogan MB. Eliminating low-value medical care in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2020;8:2370–1.PubMedCrossRef
31.
go back to reference Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy. 2013;68:816–9.PubMedCrossRef Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy. 2013;68:816–9.PubMedCrossRef
32.
go back to reference Ryan D, Tanno LK, Angier E, Clark E, Price D, Zuberbier T, et al. Clinical review: the suggested management pathway for urticaria in primary care. Clin Transl Allergy. 2022;12: e12195.PubMedPubMedCentralCrossRef Ryan D, Tanno LK, Angier E, Clark E, Price D, Zuberbier T, et al. Clinical review: the suggested management pathway for urticaria in primary care. Clin Transl Allergy. 2022;12: e12195.PubMedPubMedCentralCrossRef
33.
go back to reference Ryan D, Angier E, Gomez M, Church D, Batsiou M, Nekam K, et al. Results of an allergy educational needs questionnaire for primary care. Allergy. 2017;72:1123–8.PubMedCrossRef Ryan D, Angier E, Gomez M, Church D, Batsiou M, Nekam K, et al. Results of an allergy educational needs questionnaire for primary care. Allergy. 2017;72:1123–8.PubMedCrossRef
34.
go back to reference Cho YT, Pao YC, Chu CY. Unmet medical needs for chronic spontaneous urticaria patients: highlighting the real-life clinical practice in Taiwan. J Eur Acad Dermatol Venereol. 2016;30:41–9.PubMedCrossRef Cho YT, Pao YC, Chu CY. Unmet medical needs for chronic spontaneous urticaria patients: highlighting the real-life clinical practice in Taiwan. J Eur Acad Dermatol Venereol. 2016;30:41–9.PubMedCrossRef
35.
go back to reference Cherrez A, Maurer M, Weller K, Calderon JC, Simancas-Racines D, Cherrez OI. Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organ J. 2017;10:21.PubMedPubMedCentralCrossRef Cherrez A, Maurer M, Weller K, Calderon JC, Simancas-Racines D, Cherrez OI. Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organ J. 2017;10:21.PubMedPubMedCentralCrossRef
36.
go back to reference Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier T, et al. Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27:43–50.PubMedCrossRef Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier T, et al. Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27:43–50.PubMedCrossRef
37.
go back to reference Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy. 2016;71:1210–8.PubMedCrossRef Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy. 2016;71:1210–8.PubMedCrossRef
38.
go back to reference Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174:892–4.PubMedCrossRef Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174:892–4.PubMedCrossRef
39.
go back to reference Anto A, Maurer R, Gimenez-Arnau A, Cherrez-Ojeda I, Hawro T, Magerl M, et al. Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. Allergy. 2021;76:3810–3.PubMedCrossRef Anto A, Maurer R, Gimenez-Arnau A, Cherrez-Ojeda I, Hawro T, Magerl M, et al. Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. Allergy. 2021;76:3810–3.PubMedCrossRef
40.
go back to reference Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clin Transl Allergy. 2021;11: e12089.PubMedPubMedCentralCrossRef Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clin Transl Allergy. 2021;11: e12089.PubMedPubMedCentralCrossRef
41.
go back to reference Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.PubMedCrossRef Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.PubMedCrossRef
42.
go back to reference Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “Real-world” evidence. JAMA Dermatol. 2019;155:29–38.PubMedCrossRef Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “Real-world” evidence. JAMA Dermatol. 2019;155:29–38.PubMedCrossRef
44.
go back to reference Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: collegium internationale allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181:321–33.PubMedCrossRef Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: collegium internationale allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181:321–33.PubMedCrossRef
45.
go back to reference Hopkinson K. The role of patient-reported outcomes in the management of chronic spontaneous urticaria. Br J Nurs. 2019;28:144–50.PubMedCrossRef Hopkinson K. The role of patient-reported outcomes in the management of chronic spontaneous urticaria. Br J Nurs. 2019;28:144–50.PubMedCrossRef
46.
go back to reference Baiardini I, Fasola S, Maurer M, Weller K, Canonica GW, Braido F. Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2019;74:2542–4.PubMedCrossRef Baiardini I, Fasola S, Maurer M, Weller K, Canonica GW, Braido F. Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2019;74:2542–4.PubMedCrossRef
47.
go back to reference Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Baiardini I, Braido F. Minimal clinical important difference (MCID) of the Thai chronic urticaria quality of life questionnaire (CU-Q2oL). Asian Pac J Allergy Immunol. 2016;34:137–45.PubMed Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Baiardini I, Braido F. Minimal clinical important difference (MCID) of the Thai chronic urticaria quality of life questionnaire (CU-Q2oL). Asian Pac J Allergy Immunol. 2016;34:137–45.PubMed
48.
go back to reference Prosty C, Gabrielli S, Mule P, Noorah N, Baum S, Greenberger S, et al. Validation of the urticaria control test (UCT) in children with chronic urticaria. J Allergy Clin Immunol Pract. 2022;10(3293–8): e2. Prosty C, Gabrielli S, Mule P, Noorah N, Baum S, Greenberger S, et al. Validation of the urticaria control test (UCT) in children with chronic urticaria. J Allergy Clin Immunol Pract. 2022;10(3293–8): e2.
49.
go back to reference Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840–4.PubMedCrossRef Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840–4.PubMedCrossRef
50.
go back to reference Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical measures of chronic urticaria. Immunol Allergy Clin North Am. 2017;37:35–49.PubMedCrossRef Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical measures of chronic urticaria. Immunol Allergy Clin North Am. 2017;37:35–49.PubMedCrossRef
51.
go back to reference Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the cholinergic urticaria quality-of-life questionnaire (CholU-QoL). Clin Exp Allergy. 2018;48:433–44.PubMedCrossRef Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the cholinergic urticaria quality-of-life questionnaire (CholU-QoL). Clin Exp Allergy. 2018;48:433–44.PubMedCrossRef
52.
go back to reference Ahsan DM, Altrichter S, Gutsche A, Bernstein JA, Altunergil T, Brockstaedt M, et al. Development of the cold urticaria activity score. Allergy. 2022;77:2509–19.PubMedCrossRef Ahsan DM, Altrichter S, Gutsche A, Bernstein JA, Altunergil T, Brockstaedt M, et al. Development of the cold urticaria activity score. Allergy. 2022;77:2509–19.PubMedCrossRef
54.
go back to reference Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76:2965–81.PubMedCrossRef Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76:2965–81.PubMedCrossRef
55.
go back to reference Weller K, Ohanyan T, Hawro T, Ellrich A, Sussman G, Koplowitz J, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73:2406–8.PubMedCrossRef Weller K, Ohanyan T, Hawro T, Ellrich A, Sussman G, Koplowitz J, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73:2406–8.PubMedCrossRef
56.
go back to reference Deza G, Bertolin-Colilla M, Pujol RM, Curto-Barredo L, Soto D, Garcia M, et al. Basophil fcepsilonri expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017;97:698–704.PubMedCrossRef Deza G, Bertolin-Colilla M, Pujol RM, Curto-Barredo L, Soto D, Garcia M, et al. Basophil fcepsilonri expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017;97:698–704.PubMedCrossRef
57.
go back to reference Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Giménez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98:641–7.PubMedCrossRef Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Giménez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98:641–7.PubMedCrossRef
58.
go back to reference Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.PubMedCrossRef Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.PubMedCrossRef
59.
go back to reference Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(1139–50): e4. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(1139–50): e4.
60.
go back to reference Gilmore TM, Alexander BH, Mueller BA, Rivara FP. Occupational injuries and medication use. Am J Ind Med. 1996;30:234–9.PubMedCrossRef Gilmore TM, Alexander BH, Mueller BA, Rivara FP. Occupational injuries and medication use. Am J Ind Med. 1996;30:234–9.PubMedCrossRef
61.
go back to reference Zhou P, Zeng S, Fu L, Chen H, Li L. Efficacy and safety of intensive nonsedating antihistamines for chronic spontaneous urticaria: a meta-analysis of randomized controlled trials. Int Arch Allergy Immunol. 2022;183:796–803.PubMedCrossRef Zhou P, Zeng S, Fu L, Chen H, Li L. Efficacy and safety of intensive nonsedating antihistamines for chronic spontaneous urticaria: a meta-analysis of randomized controlled trials. Int Arch Allergy Immunol. 2022;183:796–803.PubMedCrossRef
62.
go back to reference Weller K, Ziege C, Staubach P, Brockow K, Siebenhaar F, Krause K, et al. H 1 -antihistamine up-dosing in chronic spontaneous urticaria: patients’ perspective of effectiveness and side effects – a retrospective survey study. PLoS ONE. 2011;6: e23931.PubMedPubMedCentralCrossRef Weller K, Ziege C, Staubach P, Brockow K, Siebenhaar F, Krause K, et al. H 1 -antihistamine up-dosing in chronic spontaneous urticaria: patients’ perspective of effectiveness and side effects – a retrospective survey study. PLoS ONE. 2011;6: e23931.PubMedPubMedCentralCrossRef
63.
go back to reference Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic urticaria: a Swedish registry-based cohort study on population, comorbidities and treatment characteristics. Acta Derm Venereol. 2022;102:adv00624.PubMedCrossRef Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic urticaria: a Swedish registry-based cohort study on population, comorbidities and treatment characteristics. Acta Derm Venereol. 2022;102:adv00624.PubMedCrossRef
64.
go back to reference Lachover-Roth I, Rabie A, Cohen-Engler A, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Chronic urticaria in children - new insights from a large cohort. Pediatr Allergy Immunol. 2021;32:999–1005.PubMedCrossRef Lachover-Roth I, Rabie A, Cohen-Engler A, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Chronic urticaria in children - new insights from a large cohort. Pediatr Allergy Immunol. 2021;32:999–1005.PubMedCrossRef
65.
go back to reference Torre AC, Bollea Garlatti ML, Marciano S, Posadas-Martinez ML, Parisi CAS, Mazzuoccolo LD. Real-life approach and treatment of chronic urticaria in Argentina: a national survey. Dermatol Ther. 2019;32: e13086.PubMedCrossRef Torre AC, Bollea Garlatti ML, Marciano S, Posadas-Martinez ML, Parisi CAS, Mazzuoccolo LD. Real-life approach and treatment of chronic urticaria in Argentina: a national survey. Dermatol Ther. 2019;32: e13086.PubMedCrossRef
66.
go back to reference Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.PubMedPubMedCentralCrossRef Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.PubMedPubMedCentralCrossRef
68.
go back to reference Menzies-Gow A, Jackson DJ, Al-Ahmad M, Bleecker ER, Cosio Piqueras FBG, Brunton S, et al. A renewed charter: key principles to improve patient care in severe asthma. Adv Ther. 2022;39:5307–26.PubMedPubMedCentralCrossRef Menzies-Gow A, Jackson DJ, Al-Ahmad M, Bleecker ER, Cosio Piqueras FBG, Brunton S, et al. A renewed charter: key principles to improve patient care in severe asthma. Adv Ther. 2022;39:5307–26.PubMedPubMedCentralCrossRef
69.
go back to reference Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Maurer M, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018;73:576–84.PubMedCrossRef Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Maurer M, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018;73:576–84.PubMedCrossRef
70.
go back to reference Özkan M, Oflaz SB, Kocaman N, Özşeker F, Gelincik A, Büyüköztürk S, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2007;99:29–33.PubMedCrossRef Özkan M, Oflaz SB, Kocaman N, Özşeker F, Gelincik A, Büyüköztürk S, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2007;99:29–33.PubMedCrossRef
71.
go back to reference Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420–6.PubMedCrossRef Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420–6.PubMedCrossRef
72.
go back to reference Ogłodek EA, Szota AM, Just MJ, Araszkiewicz A, Szromek AR. Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria. Neuropsychiatr Dis Treat. 2016;12:995–1004.PubMedPubMedCentralCrossRef Ogłodek EA, Szota AM, Just MJ, Araszkiewicz A, Szromek AR. Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria. Neuropsychiatr Dis Treat. 2016;12:995–1004.PubMedPubMedCentralCrossRef
73.
go back to reference Sommer R, da Silva N, Langenbruch A, Maurer M, Staubach-Renz P, Augustin M. Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. Eur J Dermatol. 2020;30:259–66.PubMedCrossRef Sommer R, da Silva N, Langenbruch A, Maurer M, Staubach-Renz P, Augustin M. Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. Eur J Dermatol. 2020;30:259–66.PubMedCrossRef
74.
75.
go back to reference Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organ J. 2021;14: 100542.PubMedPubMedCentralCrossRef Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organ J. 2021;14: 100542.PubMedPubMedCentralCrossRef
78.
go back to reference Drexel C, Bixler E, Lee J, Lang D, Eftekhari S. Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management. J Allergy Clin Immunol. 2023;151:AB138.CrossRef Drexel C, Bixler E, Lee J, Lang D, Eftekhari S. Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management. J Allergy Clin Immunol. 2023;151:AB138.CrossRef
79.
go back to reference Laires PA, Balp MM, Weller K, Winders T, Bernstein JA, O'Donoghue JEM, et al. Urticaria voices: design of a real-world study on the burden of chronic urticaria from patients' and physicians' perspectives. European Academy of Dermatology and Venereology; 2022. September 7-10; Milan, Italy Laires PA, Balp MM, Weller K, Winders T, Bernstein JA, O'Donoghue JEM, et al. Urticaria voices: design of a real-world study on the burden of chronic urticaria from patients' and physicians' perspectives. European Academy of Dermatology and Venereology; 2022. September 7-10; Milan, Italy
Metadata
Title
A Patient Charter for Chronic Urticaria
Authors
Marcus Maurer
Mónica Albuquerque
Jean-Nicolas Boursiquot
Elaine Dery
Ana Giménez-Arnau
Kiran Godse
Guillermo Guitiérrez
Amin Kanani
Gina Lacuesta
Jessica McCarthy
Simon Nigen
Tonya Winders
Publication date
22-11-2023
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2024
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-023-02724-6

Other articles of this Issue 1/2024

Advances in Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.